- Deal value: $1.3 billion equity, $1.1 billion enterprise value
- Offer price: $20 per ADS, all cash
Merck KGaA acquires Silence Therapeutics for $20 per ADS, a 130% premium, adding siRNA technology and late-stage polycythemia vera drug divesiran. Silence shares surged 126%.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.